186 related articles for article (PubMed ID: 16490736)
1. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
[TBL] [Abstract][Full Text] [Related]
2. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG
HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923
[TBL] [Abstract][Full Text] [Related]
3. A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.
Märten A; Schmidt J; Ose J; Harig S; Abel U; Münter MW; Jäger D; Friess H; Mayerle J; Adler G; Seufferlein T; Gress T; Schmid R; Büchler MW
BMC Cancer; 2009 May; 9():160. PubMed ID: 19470159
[TBL] [Abstract][Full Text] [Related]
4. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study.
Sakamoto T; Kishino M; Murakami Y; Miyatani K; Hanaki T; Shishido Y; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Fujiwara Y
Medicine (Baltimore); 2024 May; 103(21):e38292. PubMed ID: 38788030
[TBL] [Abstract][Full Text] [Related]
5. A case of metachronous oligo-hepatic and peritoneal metastases of pancreatic cancer with a favorable outcome after conversion surgery combined with perioperative sequential chemotherapy.
Tohyama T; Tanno Y; Murakami T; Hayashi T; Fujimoto Y; Takehara K; Seshimo K; Fukuhara R; Omori M; Matsumoto T
Clin J Gastroenterol; 2024 Apr; 17(2):371-381. PubMed ID: 38291249
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study.
Poiraud C; Lenne X; Bruandet A; Theis D; Bertrand N; Turpin A; Truant S; El Amrani M
World J Surg Oncol; 2024 May; 22(1):123. PubMed ID: 38711136
[TBL] [Abstract][Full Text] [Related]
7. Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers: A Retrospective Study and Meta-analysis.
Imamura T; Ohgi K; Mori K; Ashida R; Yamada M; Otsuka S; Uesaka K; Sugiura T
Ann Surg; 2024 Jun; 279(6):1025-1035. PubMed ID: 37638472
[TBL] [Abstract][Full Text] [Related]
8. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study.
Roth S; Springfeld C; Diener MK; Tjaden C; Knebel P; Klaiber U; Michalski CW; Mieth M; Jäger D; Büchler MW; Hackert T
BMJ Open; 2019 Aug; 9(8):e028696. PubMed ID: 31434770
[TBL] [Abstract][Full Text] [Related]
9. Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes.
O'Reilly EM; Cockrum P; Surinach A; Wu Z; Dillon A; Yu KH
Cancer Med; 2020 Nov; 9(22):8480-8490. PubMed ID: 32997898
[TBL] [Abstract][Full Text] [Related]
10. A commentary on 'Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study'.
Zhong F; Xieb C; Peng X; Luo J; Yang H
Int J Surg; 2024 Mar; 110(3):1331-1332. PubMed ID: 38051933
[No Abstract] [Full Text] [Related]
11. Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer.
Evans D; Ghassemi N; Hajibandeh S; Hajibandeh S; Romman S; Laing RW; Durkin D; Athwal TS
Surgery; 2024 Jun; 175(6):1470-1479. PubMed ID: 38160086
[TBL] [Abstract][Full Text] [Related]
12. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial.
Katz MH; Merchant NB; Brower S; Branda M; Posner MC; William Traverso L; Abrams RA; Picozzi VJ; Pisters PW;
Ann Surg Oncol; 2011 Feb; 18(2):337-44. PubMed ID: 20811779
[TBL] [Abstract][Full Text] [Related]
13. Impact on Survival of Early Versus Late Initiation of Adjuvant Chemotherapy After Pancreatic Adenocarcinoma Surgery: A Target Trial Emulation.
Kirkegård J; Ladekarl M; Lund A; Mortensen F
Ann Surg Oncol; 2024 Feb; 31(2):1310-1318. PubMed ID: 37914923
[TBL] [Abstract][Full Text] [Related]
14. Invited commentary for "Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer".
House MG
Surgery; 2024 Jun; 175(6):1480-1481. PubMed ID: 38627104
[No Abstract] [Full Text] [Related]
15. The Evolutionary Origins of Recurrent Pancreatic Cancer.
Sakamoto H; Attiyeh MA; Gerold JM; Makohon-Moore AP; Hayashi A; Hong J; Kappagantula R; Zhang L; Melchor JP; Reiter JG; Heyde A; Bielski CM; Penson AV; Gönen M; Chakravarty D; O'Reilly EM; Wood LD; Hruban RH; Nowak MA; Socci ND; Taylor BS; Iacobuzio-Donahue CA
Cancer Discov; 2020 Jun; 10(6):792-805. PubMed ID: 32193223
[TBL] [Abstract][Full Text] [Related]
16. C-Reactive Protein-to-Albumin Ratio to Predict Tolerability of S-1 as an Adjuvant Chemotherapy in Pancreatic Cancer.
Funamizu N; Sakamoto A; Hikida T; Ito C; Shine M; Nishi Y; Uraoka M; Nagaoka T; Honjo M; Tamura K; Sakamoto K; Ogawa K; Takada Y
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473284
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
[TBL] [Abstract][Full Text] [Related]
18. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group.
Cancer; 1987 Jun; 59(12):2006-10. PubMed ID: 3567862
[TBL] [Abstract][Full Text] [Related]
19. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Conroy T; Hammel P; Hebbar M; Ben Abdelghani M; Wei AC; Raoul JL; Choné L; Francois E; Artru P; Biagi JJ; Lecomte T; Assenat E; Faroux R; Ychou M; Volet J; Sauvanet A; Breysacher G; Di Fiore F; Cripps C; Kavan P; Texereau P; Bouhier-Leporrier K; Khemissa-Akouz F; Legoux JL; Juzyna B; Gourgou S; O'Callaghan CJ; Jouffroy-Zeller C; Rat P; Malka D; Castan F; Bachet JB;
N Engl J Med; 2018 Dec; 379(25):2395-2406. PubMed ID: 30575490
[TBL] [Abstract][Full Text] [Related]
20. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
